50 results on '"Hogan, William J."'
Search Results
2. EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
3. Pulmonary function and long-term survival in patients with PERDS after autologous hematopoietic stem cell transplantation
4. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
5. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
6. Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
7. Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
8. High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant
9. Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
10. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
11. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
12. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis
13. Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
14. Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths
15. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
16. Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH‐based algorithm distinguishes prognostic groups and outcomes
17. Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure
18. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma
19. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
20. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
21. Use of autologous stem cells cryopreserved for over 15 years in stem cell transplantation for multiple myeloma
22. Risk of relapse in patients receiving azithromycin after allogeneic HSCT
23. Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
24. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation
25. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant
26. Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a ‘graft versus host’-like syndrome and poor outcomes
27. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis
28. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
29. Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system
30. The D-index is not correlated with invasive fungal infection during the early-post engraftment phase among allogeneic hematopoietic stem cell transplant recipients
31. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma
32. Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant
33. Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function
34. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
35. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation
36. Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy
37. Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma
38. Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response
39. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
40. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis
41. Momelotinib therapy for myelofibrosis: a 7-year follow-up
42. Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
43. Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis
44. Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease
45. Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis
46. Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation
47. Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant
48. Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia
49. Therapeutic Applications of Non-Myeloablative Hematopoietic Stem Cell Transplantation in Malignant Disease
50. Inertial fusion energy development beyond 2000
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.